Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Expanded indications for bioblanket soft tissue repair patch
October 23rd, 2005
Kensey Nash Corporation (KNSY) announced that the U.S. Food and Drug Administration (FDA) has allowed expanded indications of its BioBlanket Surgical Mesh. The expanded indications specifically allow the product to be used for the repair of hernias and reinforcement of soft tissue in rotator cuff repair surgery, two of the important target markets for the technology. The expanded indication also allows the product to be used in a wide variety of other surgical procedures, including repair of defects in the thoracic wall, rectal, and pelvic floor reconstruction procedures, among others. The BioBlanket product is a Kensey Nash proprietary resorbable...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
